A Randomized, Double-blind, Two-group Parallel, Positive-controlled Clinical Phase I Trial Comparing the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of CMAB818 and Lucentis in Patients With Wet Age-related Macular Degeneration
Latest Information Update: 02 Apr 2024
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Shanghai Biomabs Pharmaceuticals
- 25 Mar 2024 Status changed from active, no longer recruiting to completed.
- 05 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2022 Planned End Date changed from 1 Jul 2022 to 1 May 2023.